Factors associated with North–South research collaboration focusing on HIV/AIDS: lessons from ClinicalTrials.gov

Hesborn Wao1, Yan Wang1,2,3*, Melvin A. Wao4 and Juliana A. Were5

Abstract

Background: A North–South (N–S) research collaboration is one way through which research capacity of developing countries can be strengthened. Whereas N–S collaboration in HIV/AIDS area may result in research capacity strengthening of Southern partners, it is not clear what factors are associated with this type of collaboration. The study aims to characterize N–S research collaboration focusing on HIV/AIDS and to determine factors associated with such N–S research collaborations.

Methods: Clinical trial data on HIV/AIDS-related studies conducted between 2000 and 2019 were obtained from ClinicalTrials.gov. Using these data, we characterized N–S collaborative studies focusing on HIV/AIDS and summarized them using frequencies and percentages. To determine factors associated with these studies, we used logistic regression and reported results as adjusted odds ratios with Wald 95% confidence intervals.

Results and discussion: Of the 4,832 HIV/AIDS-related studies retrieved from the registry, less than one-quarter (n = 1133, 23%) involved a Southern institution, with 77% of these studies classified as N–S collaborations. Majority of these studies have single PI (50%), are conducted at single location (39%); have large sample sizes (41%); are federally-funded (32%) or receive funding from other sources (32%); are intervention studies (64%); and involve a mixture of male and female participants (58%) and adult participants (54%). Single PIs (as opposed to multiple PIs) were more likely to be from the North than South institution (odds ratio = 5.59, 95%CI: 4.16 – 11.57). Trend analyses showed that N–S research collaborations produced HIV/AIDS-related studies at a faster rate than S–S research collaborations. N–S collaborations involving female or children produced HIV/AIDS-related studies between 2000 and 2019 at a significantly faster rate than S–S collaborations involving females and children during the same period. Holding other factors constant, N–S collaborative research focusing on HIV/AIDS are associated with: multiple PIs as opposed to single PI, multiple institutions as opposed to a single institution, multiple locations as opposed to a single location, large number of participants as opposed to small sample sizes, and public funding as opposed to industry funding. Almost half of these studies had a Northern PI only, about one-third had a Southern PI only, and much fewer had PIs from both North and South. However, these studies were less likely to receive funding from other sources than industry funding.

Conclusions: HIV/AIDS-related research is increasingly becoming a more collaborative global research involving more N–S collaborations than S–S collaborations. Factors associated with N–S collaborative studies focusing on HIV/AIDS research.
Introduction

Most developing countries have limited capacity to conduct scientific research due to insufficient research training, inadequate financial and material resources, and the emigration of researchers to the developed world [1]. In addition, uptake of research findings into policy and practice is limited in developing countries due to researchers’ inadequate knowledge translation skills [2]. Strengthening research capacity of developing countries can enable them to conduct locally-relevant, high-priority research, and thus contribute to their own national health system and policymaking process [3]. By research capacity strengthening (RCS) we refer to any efforts aimed at increasing the ability of individuals and institutions to undertake high-quality research and to engage with the wider community of stakeholders [4].

A North–South (N–S) research collaboration is one way through which research capacity of developing countries can be strengthened [5]. In the context of this study, a N–S collaboration is whereby researchers from a developed country (North) and a developing country (South) agree to jointly conduct research. It is a mechanism through which to channel resources to support scientific and technological activities in less developed countries [6]. The collaboration may involve two institutions (universities, research organizations, government agency, etc.) conducting joint research in a single country or in multiple institutions in several countries. Whereas most of the high income countries are located in the northern hemisphere, the North/South division is not totally based on actual geographical location. It is also based on social, economic, and political differences among countries [7]. Examples of countries classified under global North include United States of America, Canada, United Kingdom, Israel, Japan, Singapore, South Korea, Australia, New Zealand, France, Germany, Italy, and Russia. Classified under global South include countries in Africa, Latin America, Asia, Brazil, India, China, Indonesia, and others. Effective N–S collaboration can enable researchers from partnering countries to benefit from knowledge of diverse settings [8]. Funds attracted, complementary expertise, and resources accumulated through N–S collaboration can strengthen research capacity of Southern countries [9].

Given the complexity of managing HIV/AIDS, studies focusing on HIV/AIDS often use a multi-disciplinary and multi-institutional approach aimed at evidence-based prevention and care practices that are applicable across country contexts [10, 11]. Studies examining the potential benefits of N–S collaboration tend to focus on formal partnerships in the form of consortia [5, 12–15] or non-academic partnerships [16]. However, increasing number of researchers are engaged in conducting clinical trials, a form of partnership whose formation and operation differ from that of consortia or non-academic partnerships. Whereas N–S collaboration in HIV/AIDS area may result in research capacity strengthening of Southern partners, neither have such collaborations been characterized nor is it clear what factors are associated with them.

ClinicalTrials.gov, a publicly accessible online registry of clinical trials conducted in the United States and in many countries throughout the world (ClinicalTrials.gov), provides a credible data source for examining factors associated with N–S research collaboration. Established in 2000 and managed by the US National Library of Medicine, it is the largest clinical trials database, holding over 329,000 trials from 209 countries. It contains over 80% of all clinical studies in the WHO portal [17]. Comparing six high-profile online international clinical trial registers (i.e., Pan African Clinical Trials Register; the South African National clinical Trials Register [SANCTR]; the European Union Clinical trials Registry; the WHO International Clinical Trials Registry Platform [ICTRP]; and International Standard Randomized Controlled Trial Number [ISRCTN]), a heuristic evaluation based on five key usability factors ranked it the best register [18–20].

This study aims to characterize N–S research collaboration focusing on HIV/AIDS and determine factors associated with such collaborations. As more institutions engage in collaborative research focusing on HIV/AIDS, knowing factors associated with N–S collaboration in HIV/AIDS-related research can inform the constitution and management of such partnerships. In addition, knowledge of predictive factors of N–S collaboration may enhance N–S international cooperation and international support for implementing effective and targeted capacity-building in developing countries [3]. In this study,
data from ClinicalTrials.gov are analyzed to answer the following research questions (RQs): 1) What are the characteristics of N–S collaborative studies focusing on HIV/AIDS-related research? 2) What factors are associated with N–S research collaborations focusing on HIV/AIDS-related research?

**Methods**

**Data source**

Clinical trials registered in https://clinicaltrials.gov were downloaded on March 3, 2020 using keyword “HIV/AIDS.” We selected “All Studies” for study type and results, “Completed” for study status, and “All” for gender/sex of participants. We selected all 23 variables, including interventions, study type, funding type, study design, and so on.

**Outcome variable and covariates**

We defined the outcome variable based on information provided in the “Sponsor/Collaborator” field. If there were both Northern institution and Southern institution, we defined the clinical trial as a “North–South” collaboration. If it involved only institutions from the South, we defined it as a “South-South” collaborations. The consistency of this coding was checked by two different authors.

We derived several covariates from the variables collected in the registry database. We classified the Principal Investigators (PI) as single PI or Multiple PIs; study design was classified as interventional or observational; and study duration was derived from the start date and completion date. Short study was defined as two years or less, medium length as two to five years, and long length as five years and more. The size of collaboration was defined by number of institutions involved in the study: three or more institutions versus one institution. A similar definition was used for the number of study locations. The study size was defined by the number of participants in the study: small (< 30 participants), medium (30 to 250), and large (250 +). Funding resources were classified into three categories: industry funded only clinical trials were funded by private sectors such as pharmaceutical companies; public-funded clinical trials were defined if any funding resource was from federal agencies such as NIH; and clinical trials funded by other funders such as universities, community-based organizations, philanthropies, and so on. Table 1 presents the variables used in the analyses, their definition, coding, or derivation.

**Data analysis**

In characterizing HIV/AIDS-related studies conducted between 2000 and 2019, we hypothesized here would be no difference in the rate of producing studies based on: (1) type of collaboration (N–S vs. S–S), (2) gender of study subjects (N–S focusing on females only vs S–S focusing on females only), and (3) age of study subjects (N–S focusing on children only vs S–S focusing on children only). We used univariate, bivariate and multivariate analysis to find the factors that were highly associated with the N–S collaboration among all these clinical trials. We reported the frequency and percentage for each variables in the univariate analysis. In the bivariate analysis, the association between each covariate with the N–S collaboration was reported with p-values. In multivariate analysis, we used logistic regression and reported adjusted odds ratios (AOR) with Wald 95% confidence intervals (95% CI). Statistical analyses were performed using SAS software, version 9.4 (SAS Institute, Cary, NC, USA).

**Results**

Of the 4,832 HIV/AIDS-related studies retrieved from the registry, less than one-quarter (n=1133, 23%) involved at least a Southern institution. However, about three-quarters (871, 77%) of these studies were N–S research collaborations. Figure 1 presents the world map of N–S collaborative HIV/AIDS-related research conducted between 2000 and 2019. Globally, only two Northern countries (i.e., the United States and France) were engaged in N–S collaborations involving the largest trials (n=200 to 2000 participants) compared to four Southern countries (i.e., Brazil, Spain, Thailand, and South Africa). However, more Northern countries (i.e., Germany, Italy, United Kingdom, Argentina, & Canada) were engaged in N–S collaboration involving the second largest number of trials (n=100 to 200) compared to two Southern countries (Kenya & Uganda). Fewer Northern countries (e.g., Russia & Georgia) were engaged in N–S collaboration involving the smallest number of trials (n=1 to 10 participants) compared to Southern countries (Niger, Burkina Faso, Morocco, & Iran).

The number of completed N–S collaborative studies focusing on HIV/AIDS increased steadily from 7 in 2000 to 73 in 2011, declined to 55 in 2015 but rose to 82 in 2018 before declining to 50 in 2019 (Fig. 2). We noticed a similar trend for completed S–S collaborative research focusing on HIV/AIDS: the number of S–S collaborate research increased from 3 in 2000 to 26 in 2011, declined to 15 in 2013 but rose to 55 in 2014 before declining to 18 in 2019. Overall, there is an increasingly widening gap in number of N–S and S–S HIV-AIDS-related studies conducted between 2000 and 2019. Figure 2 shows that the slope (Δ=4.0812) of the regression line for number of N–S collaborative studies between 2000 and 2019 is much steeper than the slope (Δ=41.3015) of the regression line for number of S–S collaborative studies during the same...
Table 1 Variables used in the analysis

| Variable                      | Definition, Coding, and Derivation                                                                 |
|-------------------------------|-----------------------------------------------------------------------------------------------------|
| 1 Type of collaboration*      | If a study involved at least one country in the South and at least one country in the North then type of collaboration is N–S (coded 1), else South-South (coded 0). Type of collaboration was derived from data about “Sponsor/Collaborators” and “Locations” |
| 2 Principal investigators     | A dichotomous variable indicating whether the study involved a single principal investigator (PI), or Study Director, or Chair (coded 0) or multiple PIs (coded 1) |
| 3 Size of collaboration       | A continuous variable indicating number of institutions involved in the collaboration. This variable was categorized into: 3+ institutions (coded 2) vs. 2 institutions (coded 1) vs. 1 institution (coded 0). This variable was derived from data about “Sponsor/Collaborators” and “Locations” |
| 4 Study location*             | A continuous variable indicating total number of study locations. This variable was categorized into: 3+ locations (coded 2) vs. 2 locations (coded 1) vs. a single location (coded 0) |
| 5 Study size                  | A continuous variable indicating total number of participants enrolled in the study. This variable was derived from data about “Enrollment.” Study size was categorized into large (100+ participants—coded 2) vs. medium (50–99 participants—coded 1) vs. small size (<50 participants—coded 0) |
| 6 Funding source              | A categorical variable describing the organization that provides funding or support (e.g., for activities related to study design, implementation, data analysis, and reporting) for a clinical study. According to ClinicalTrials.gov, organizations listed as sponsors and collaborators are considered the funders of the study. Whereas the database has four types of funders (U.S. NIH; other US Federal agencies; Industry; and All Others), these were re-coded as follows: public-funded including U.S. NIH and other federal agencies (coded 0), industry-funded such as pharmaceutical and device companies (coded 1), jointly funded by public and industry (coded 2), or Other including individuals, universities, community-based organizations, (coded 3). This variable was derived from data about “Sponsor/Collaborators” |
| 7 Study design                | A dichotomous variable indicating whether a trial was interventional (coded 1) or observational study (coded 0). Briefly, an interventional study is whereby the investigator assigns participants to groups that receive one or more interventions (or no intervention) so that the effects of the interventions on biomedical or health-related outcomes can be evaluated whereas observational study is whereby there is no assignment of participants to a specific intervention, rather participants are identified as belonging to study groups and are assessed for biomedical or health outcomes |
| 8 Gender                      | A categorical variable indicating participants’ self-representation of gender identity. Gender was coded 0 if a study include males only, 1 if it includes females only, and 2 if it includes a mixture of males and females |
| 9 Age                         | A categorical variable indicating study participants’ age group. Age was coded 0 if study include only adults (age 18 and above), 1 if it includes only children (age 17 or below), and 2 if it includes a mixture of adults and children |
| 10 Study duration (in years)*  | A continuous variable indicating the number years taken from start to completion of the study. To compute study duration, we subtracted “Study Start Date” (i.e., the date on which the first participant was enrolled in a clinical study) from “Study Completion Date” (i.e., the date on which the last participant was examined or received an intervention). Study duration was categorized into long (coded 2) vs. medium (coded 1) vs short (coded 0). If data on “Study Completion Date” were missing, then “Primary Completion Date” was used and if this was also missing, then date “Last Verified” was used. If only month and year were recorded, then the first day of the month was entered |

* Variable created by research team (not directly available from ClinicalTrials.gov); Code 0 is the reference category

period. Using t-test, the null hypothesis (H0: the slopes are equal) is rejected. We conclude that N–S research collaborations produced HIV/AIDS-related studies at a faster rate than S–S research collaborations.

Majority of N–S collaborative studies on HIV/AIDS were characterized as having single PI (50%), single location (39%), large sample size (41%), federally-funded (32%) or receive funding from other sources (32%), intervention studies (64%), involved a mixture of male and female participants (58%) as well as adult participants (54%) (Table 2). Single PIs (as opposed to multiple PIs) were more likely to be from the North than South institution (odds ratio = 5.59, 95% CI: 4.16–11.57). Results of bivariate analysis using Chi-square test showed that, except for study design, the remaining variables were each statistically significantly associated with the N–S collaboration. Tests to determine if the data met the assumption of collinearity indicated that multicollinearity was not a concern.

There were 175 N–S collaborative studies focusing on HIV/AIDS that involved female participants only (16%). There was a steep rising trend in number of N–S collaborative research involving female participants during the period 2000 to 2011 before a decline in 2014 (Fig. 3). In contrast, the number of S–S collaborative studies involving female rose from 2004 to 2006, peaking in 2009 and 2014. Overall, Fig. 3 shows that N–S collaborations involving female participants only produced HIV/AIDS-related studies between 2000 and 2019 at a significantly faster rate than S–S collaborations involving females only during the same period (Δ = 0.8211 vs. Δ = 0.1797).

Similarly, only 81 completed N–S collaborative studies focusing on HIV/AIDS involved children (7%). A general rising trend was reported between 2000 and 2016, with peaks in 2013 and 2016 (Fig. 4). A steady decrease in the number of these studies was reported after 2016. In contrast, except for 2008, 2011 and 2012 when there were three S–S collaborative studies on
HIV/AIDS involving children, there was no such studies between 2000 and 2007 and only one such study between 2013 and 2019. In sum, Fig. 4 shows that N–S collaborations involving children only produced HIV/AIDS-related studies between 2000 and 2019 at a significantly faster rate than S–S collaborations involving children during the same period ($\Delta = 0.2917$ vs. $\Delta = 0.0789$). However, this result should be interpreted cautiously given low fit statistics ($R^2 = 53.8\%$ and $R^2 = 19.8\%$, respectively).

Multivariate analysis were conducted using logistic regression, with nine covariates included. We found that, holding other factors constant, N–S collaborative research focusing on HIV/AIDS were highly associated with: multiple PIs as opposed to single PI, multiple institutions as opposed to a single institution, three or more locations as
opposed to a single location, large number of participants as opposed to small sample sizes, and federal funding as opposed to industry funding (Table 3). Additional analyses showed that almost half of the studies (49%) had Northern PI only, about one-third had Southern PI only (32%), and much fewer had PIs from both North and South (19%). N–S collaborative research focusing on HIV/AIDS did not vary by study design (RCTs vs. observational) or study duration (long vs. medium vs short duration).

Discussion
The number of N–S collaborative research focusing on HIV/AIDS increased between 2000 and 2011. This rising trend coincides with findings from a secondary data

| Table 2 Characteristics of N–S collaborative studies focusing on HIV/AIDS |
|----------------------|------------------|------------------|------------------|------------------|
| Variable                          | South-South (262, 23%) | North-South (871, 77%) | Total (1133, 100%) | P-value |
|-----------------------------------|------------------------|------------------------|----------------------|---------|
| Principal investigator (PI)       |                        |                        |                      | <0.0001 |
| Multiple PI                       | 41                     | 3.6                    | 307                  | 27.1    | 348                      | 30.7    |
| Single PI                         | 221                    | 19.5                   | 564                  | 49.8    | 785                      | 69.3    |
| Size of the collaboration+1       |                        |                        |                      | <0.0001 |
| 3+ institutions                   | 35                     | 3.1                    | 371                  | 32.7    | 406                      | 35.8    |
| 2 institutions                    | 87                     | 7.7                    | 288                  | 25.4    | 375                      | 33.1    |
| 1 institution                     | 140                    | 12.4                   | 212                  | 18.7    | 352                      | 31.1    |
| Locations                         |                        |                        |                      | <0.0001 |
| 3+ locations                      | 45                     | 4.0                    | 323                  | 28.5    | 368                      | 32.5    |
| 2 locations                       | 22                     | 1.9                    | 103                  | 9.1     | 125                      | 11.0    |
| 1 location                        | 195                    | 17.2                   | 445                  | 39.3    | 640                      | 56.5    |
| Study size+2                      |                        |                        |                      | <0.0001 |
| Large (250+ participants)         | 65                     | 5.7                    | 468                  | 41.3    | 533                      | 47.0    |
| Medium (30–250)                   | 142                    | 12.5                   | 319                  | 28.2    | 461                      | 40.7    |
| Small (<30 participants)          | 55                     | 4.9                    | 84                   | 7.4     | 139                      | 12.3    |
| Funding Source                    |                        |                        |                      | <0.0001 |
| Federal                           | 7                      | 0.6                    | 357                  | 31.5    | 364                      | 32.1    |
| Industry                          | 24                     | 2.1                    | 155                  | 13.7    | 179                      | 15.8    |
| Other                             | 231                    | 20.4                   | 359                  | 31.7    | 590                      | 52.1    |
| Study Design                       |                        |                        |                      | 0.3799  |
| RCTs                              | 211                    | 18.6                   | 722                  | 63.7    | 933                      | 82.4    |
| Observational                     | 51                     | 4.5                    | 149                  | 13.2    | 200                      | 17.6    |
| Gender of participants            |                        |                        |                      | <0.0001 |
| Male                              | 20                     | 1.8                    | 36                   | 3.2     | 56                       | 5.0     |
| Female                            | 17                     | 1.5                    | 175                  | 15.5    | 192                      | 17.0    |
| Mixed (male and female)           | 225                    | 19.9                   | 659                  | 58.2    | 884                      | 78.0    |
| Age of participants               |                        |                        |                      | <0.0001 |
| Child                             | 9                      | 0.8                    | 81                   | 7.2     | 90                       | 7.9     |
| Adult                             | 229                    | 20.2                   | 613                  | 54.1    | 842                      | 74.3    |
| Mixed (child and adult)           | 24                     | 2.1                    | 177                  | 15.6    | 201                      | 17.7    |
| Study duration                    |                        |                        |                      | <0.0001 |
| Short (2 years or less)           | 137                    | 12.1                   | 302                  | 26.7    | 439                      | 38.7    |
| Medium (2–5 years)                | 106                    | 9.4                    | 441                  | 38.9    | 547                      | 48.3    |
| Long (5 years or more)            | 19                     | 1.7                    | 128                  | 11.3    | 147                      | 13.0    |

+1 = based on number of institutions; +2 = based on number of participants enrolled
analysis of 264,102 academic papers focusing on HIV/AIDS reported in the Scopus during the period 1985 to 2012 [21]. In that study, a rising trend was reported between 2000 and 2012 in annual publication rate, average number of authors per paper, and number of countries contributing to HIV/AIDS research. Our finding that United States was among the countries that was engaged in N–S collaboration involving largest trials is consistent with the finding from Elsevier’s Analytical Services [30] in which the United States emerged the top producer of HIV/AIDS-related research (followed by United Kingdom, South Africa, and China). It is not surprising that South Africa tops among largest producer of HIV/AIDS-related publications given that it has the highest HIV burden in the continent. In our study, we find that N–S collaborative research focusing on HIV/AIDS were more likely to have multiple institutions. Partnership brought together stakeholders with a common goal and more productive than the sum of their individual efforts [22]. We also found that N–S collaborative research focusing on HIV/AIDS were more likely to have multiple PIs as opposed to a single PI. In addition, almost half had Northern PI only, about one-third had Southern PI only, and much fewer had PIs from both North and South. These findings suggest an opportunity to enhance research capacity of Southern collaborators, for example, by encouraging them to serve as PIs, co-PIs, Study Director, or Chair. Active involvement was considered essential by researchers in judging the merits of active participation in global health research collaborations [23]. Similarly, in a study examining the factors that impact equitable global health partnerships, having a US partner actively involved in education/research in LMIC setting was among the top ranked enablers of equitable partnership [29]. However, if Southern collaborators seldom lead the research project, their chances of being research leaders are diminished. This scenario has been described as “parachutic” or “parasitic” research partnership whereby a Northern partner make use of infrastructure, personnel, and participants from the South but

| Table 3 Prediction of N–S Research Collaboration Focusing on HIV/AIDS |
|-----------------|----------------|---------------|
| Effect | AOR | 95% CI |
| Number of PIs | | |
| Multiple vs. single | 2.04** | 1.32 | 3.14 |
| Size of collaboration | | |
| 3 + institutions vs. single | 4.78*** | 2.99 | 7.63 |
| 2 institutions vs. single | 1.71** | 1.16 | 2.53 |
| Study location | | |
| 3 + locations vs. 1 location | 1.86** | 1.18 | 2.92 |
| 2 + locations vs. 1 location | 1.58 | 0.89 | 2.81 |
| Study size | | |
| Large vs. small | 1.97* | 1.16 | 3.34 |
| Medium vs. small | 0.96 | 0.59 | 1.56 |
| Funding Source | | |
| Federal vs industry only | 4.45** | 1.80 | 11.00 |
| Other vs industry only | 0.23*** | 0.14 | 0.39 |
| Study design | | |
| RCTs vs observational | 1.11 | 0.70 | 1.76 |
| Gender | | |
| Mixed vs male | 1.45 | 0.69 | 3.06 |
| Female vs male | 5.06** | 2.05 | 12.49 |
| Age | | |
| Child vs adult | 3.13** | 1.43 | 6.86 |
| Mixed vs adult | 2.04** | 1.19 | 3.50 |
| Duration of study | | |
| Long vs short | 1.60 | 0.83 | 3.07 |
| Medium vs. short | 1.31 | 0.90 | 1.91 |

*p < 0.05, ** p < 0.01, *** p < 0.001
not actively engaging Southern partners. This damning approach has no future in global health [24].

We found N–S collaborative research on HIV/AIDS were more likely to focus on vulnerable populations. Compared to S–S collaborative research, N–S are five times more likely to study females than males and three times more likely to study children than adults. It might be related to the fact that many studies reported that vulnerable populations such as adolescent females and young women account for a larger proportion of new HIV infections and prevalence cases [25–28]. We found the N–S collaborative research focusing on HIV/AIDS were more likely to involve large number of participants. In the context of HIV/AIDS, large studies could be more informative and more effective to compare the intervention programs.

We provide suggestions for improvement of ClinicalTrials.gov registry. For sponsor and/or collaborating institutions, we suggest inclusion of country besides name of institution. We found it more informative to include the institutional affiliation of the PIs instead of reporting only the name of PI. We suggest that publication list contains only studies related to the clinical trial. We found that some variables were missing for some studies. For example, the number of participants, start date, completion date, PIs, and other data elements. There were also errors in some studies, for example, the number of participants reported as 1 or 200,000. To circumvent some of these reporting issues, ClinicalTrials.gov may need to revise the list of mandatory fields to facilitate accurate assessment of registered trials. The registry should be updated regularly.

In this study, we only included completed clinical trials registered in ClinicalTrials.org before March 2020. We were limited to the variables collected in the registry. Though we operationalized additional variables (e.g., whether PI is from North, South, or both; duration of study; size of collaboration; and geographical scope of study location) and included them in our analysis, there are other factors that may be associated with N–S research collaborations but are neither collected (e.g., amount of grant received for the trial) nor accurately reported (e.g., number of publications from the trial). Whether a trial involved an institution from the North or South was largely derived from “Sponsor/Collaborators” and/or “Locations” fields by examining name of country. Some Northern institutions have established non-profit research organizations in the South to manage their research activities. Classifying such institutions as either North or South is tricky. For example, the International Center for AIDS Care and treatment Programs (ICAP) in Swaziland is affiliated with Columbia University. Should ICAP be considered a Northern institution regardless of where it operates? Should Malawi-Liverpool-Wellcome Trust Clinical Research Program be classified as a Southern or Northern institution or both? Should AIR, Choma, Zambia, which is affiliated with Columbia University, be considered a Southern institution? In our context, we classified such institutions as belonging to South because they are operated in the South.

This study focused on N–S research collaboration in the area of HIV/AIDS. Future researchers can examine other diseases or conditions such as cancer and COVID-19. It would be interesting to quantify research productivity (e.g., number of publications and other products) arising from N–S collaboration as well as factors associated with research productivity. However, to undertake such investigations, the research team should invest in further data collection because publications listed in the database were not all related to the clinical trial. For example, the study NCT01789138 which had start date and completion dates of Jan 2013 and December 2014 respectively, had six publications between 2000 and 2012. The publication predates the study commencement suggesting the studies are unlikely to be based on data collected during the study period. Besides focusing on number of publications, future researchers should assess impact of the publications as measures of the quality of N–S research collaborations. Similarly, rather than report that number of collaborating partner matters in a N–S research collaboration focusing on HIV/AIDS, even more informative is the composition of the institutions (public or private, university-based or research organizations etc.). Does it matter whether majority of the institutions are from North or South? Such information is linked to amount of funds that a collaborating institution receives, an important consideration when engaging in a multi-institutional grant. By paying attention to these highlighted areas, future researchers can better characterize N–S research collaborations by looking at the suggested dimensions.

As with studies employing secondary data, this study has some limitations. First, we used only one registry (clinicaltrials.gov). We are not sure if our findings would be different had we used other registries (e.g., the Pan African Clinical Trials Register; the South North–South Research Collaborations, SANCTR; the European Union Clinical trials Registry; the WHO ICTRP; and the ISRCTN). This could be the focus of future studies. Whereas, we were limited to variables reported in the registry, we did attempt to operationalize some variables and used these in our analysis, for example, developing the N–S versus S–S dichotomy for use as the outcome of interest.
Conclusions
To our knowledge, this is the first characterization of N–S collaborative studies in clinical trials registry that focus on HIV/AIDS. Our findings indicate that HIV/AIDS research is increasingly becoming a more collaborative global research involving more N–S collaborations than S–S collaborations. A number of factors are associated with N–S collaborative studies focusing on HIV/AIDS. These include multiple PIs, multiple institutions, multiple locations, large sample size, federal funding, and vulnerable populations, specifically women and children. We provide suggestions for improvement of ClinicalTrials.gov registry. Our results inform future design and implementation of N–S research collaborations in this area.

Acknowledgements
Special thanks to the Government of the United States for making ClinicalTrials.gov registry publicly available for researchers.

Authors’ contributions
HW conceptualized and designed the study; YW and HW retrieved data from ClinicalTrials.gov, defining additional variables; MW and JW coded new variables and extracted additional data; YW conducted data analysis; HW wrote the first draft; all authors revised the manuscript and provided input. All authors read and approved the final manuscript.

Funding
This work was supported by NIH [Grant Number T32MH080634] and National Institute on Minority Health and Health Disparities [Grant Number NIMHD #1T37MD014251].

Availability of data and materials
The datasets used during the current study are available from the corresponding author on reasonable request.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 African Population and Health Research Center, APHRC Campus, Manga Close, Off Kirawa Road, P.O. Box 10787-00100, Nairobi, Kenya. 2 Dornsife School of Public Health, Urban Health Collaborative, Drexel University, 3600 Market Street, 7th Floor, Philadelphia, PA, USA. 3 Division of Infectious Diseases, University of California, Los Angeles, 10833 La Conte Ave, Los Angeles, CA 90095, USA. 4 United States International University-Africa (USIU-Africa). Off USIU Road, Off Thika Road Exit 7, P. O. Box 14634-00800, Nairobi, Kenya. 5 The Management University of Africa (MUA), Popo Rd, Off Mombasa Road, Bellevue, South C., P. O. Box 29677-00100, Nairobi, Kenya.

Received: 17 April 2021 Accepted: 31 July 2021 Published online: 25 August 2021

References
1. Ghaffar A, Isselmuiden C, Zicker F. Changing mindsets: Research capacity strengthening in low- and middle-income countries. Council on Health Research for Development (COHRED), Geneva, Switzerland, 2008.
2. Murunga VI et al. Review of published evidence on knowledge translation capacity, practice and support among researchers and research institutions in low-and middle-income countries. Health Res Pol Syst. 2020;18(1):16.
3. Cash-Gibson L, Guerra G, Salgado-de-Snyder VN. SDH-NET: a South–North-South collaboration to build sustainable research capacities on social determinants of health in low-and middle-income countries. Health Res Pol Syst. 2015;13(1):45.
4. ESSENCE on Health Research. Seven principle for strengthening research capacity in low-and-middle-income countries: Simple ideas in a complex world ESSENCE Good practice document series. 2014. Retrieved July 29, 2021, from https://www.who.int/tdr/publications/ESSENCE_report2014_OK.pdf?ua=1.
5. Fånman R, et al. Successes and challenges of north–south partnerships—key lessons from the African/Asian regional capacity development projects. Glob Health Action. 2016;9(1):30522.
6. Gaillard JF. North-South research partnership: is collaboration possible between unequal partners? Knowl Policy. 1994;7(2):31–63.
7. United Nations. What is South-South cooperation and why does it matter? Department of Economic Affairs. 2019. Retrieved July 29, 2021, from https://www.un.org/development/desa/en/news/intergovernmental-coordination/south-south-cooperation-2019.html.
8. Michelet C, Bruno S, Bishnu Raj U, Urs Wiesmann W. Research partnerships: the benefits of North-South collaboration (Evidence for Policy Series, Global Edition 15). Bern: NCCR North-South. 2013. Retrieved July 29, 2021, from https://borders.unibe.ch/46604/.
9. Van der Veken K, et al. Research capacity building through North–South–South networking: towards true partnership? An exploratory study of a network for scientific support in the field of sexual and reproductive health. Health Res Pol Syst. 2017;15(1):39.
10. Magnus M, Castel A. Breaking down the silos: developing effective multidisciplinary HIV research teams. AIDS Behav. 2016;20(2):273–80.
11. McCoy CB, Bengoa AJ, McBride DC, Foley BT, Puri S, Mendez AJ, Shapshak P. Multidisciplinary approach to HIV/AIDS: Historical perspective. Global Virol- ogy II-HIV and NeuroAIDS. 2017. Springer. p. 1–20.
12. Ezeih AC, et al. Building capacity for public and population health research in Africa: the consortium for advanced research training in Africa (CARtA) model. Glob Health Action. 2010;3(1):5693.
13. Hoffman K, et al. Addressing research capacity for health equity and the social determinants of health in three African countries: the INTREC programme. Glob Health Action. 2013;6(1):19668.
14. Mirzoev T, et al. Assessment of capacity for health policy and systems research and analysis in seven African universities: results from the CHEP-SAA project. Health Policy Plan. 2014;29(7):831–41.
15. Tagoe N, et al. Managing health research capacity strengthening consortia: a systematic review of the published literature. BMJ Global Health. 2019;4(2):e001318.
16. MBUGO L et al. Approaches and impact of non-academic research capacity strengthening training models in sub-Saharan Africa: a systematic review. Health Res Pol Syst. 2015;13(1):30.
17. Califf RM, et al. Characteristics of clinical trials registered in ClinicalTrials.gov. 2007–2010. JAMA. 2012;307(17):1838–47.
18. Sibanda M, Summers R, Meyer JC. A comparison of five international clinical trial registers with the South African register for access to information and usability. Pan Afr Med J. 2018;29(1):1–7.
19. Zarin DA, et al. The ClinicalTrials.gov results database—update and key issues. New Engl J Med. 2011;364(9):852–60.
20. Goswami ND, et al. The state of infectious diseases clinical trials: a systematic review of ClinicalTrials.gov. PLoS ONE. 2013;8:10.
21. Bakeh AB, Ghaﬀarazadehgan N. Global trends and regional variations in studies of HIV/AIDS. Sci Rep. 2017;7(1):1–8.
22. Corbin JH, Mittelmark MB. Partnership lessons from the Global Programme for Health Promotion Effectiveness: a case study. Health Promot Int. 2008;23(4):365–71.
23. Parker M, Kingori P. Good and bad research collaborations: researchers’ views on science and ethics in global health research. PLoS ONE. 2016;11:10.
24. Health The Lancet Global. Closing the door on parachutes and parasites. Lancet. 2018;6(6):e593.
25. IHSN. AIDS impact survey II 2004: Botswana, 2004. : National AIDS Coordinating Agency and Central Statistics Office, 2004.
26. Ciaranello A, et al. Incidence of World Health Organization stage 3 and 4 events, tuberculosis and mortality in untreated, HIV-infected children enrolling in care before 1 year of age: an IeDEA (International Epidemiologic Databases To Evaluate AIDS) East Africa regional analysis. Pediatr Infect Dis J. 2014;33(6):623–9.
27. Girum T, et al. Gender disparity in epidemiological trend of HIV/AIDS infection and treatment in Ethiopia. Arch Public Health. 2018;76(1):51.
28. Kempton J, et al. Most new HIV infections, vertical transmissions and AIDS-related deaths occur in lower-prevalence countries. J Virus Erad. 2019;5(2):92.
29. Martin NA, et al. Bending the arc towards equitable partnerships in global health and applied training. Ann Global Health. 2019;85(1):130. https://doi.org/10.5334/aogh.2564.
30. Analytical Services. HIV/AIDS research insights: impacts, trends, opportunities. 2019. Elsevier. Retrieved July 30, 2021, from: https://www.elsevier.com/__data/assets/pdf_file/0004/944806/HIV_AIDS-research-insights_report_health-analytics_RI_WEB.pdf

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.